Retina 2007 (page 5)

Article

blah

1, 2, 3, 4, 5

2008: the year for combining approaches?
So what do our experts think awaits us in 2008? Will we see combination therapy overtake anti-VEGF monotherapy as a treatment of choice in the treatment of AMD? Will we see the launch of even better instrumentation for vitreoretinal surgery? Will the manufacturers of imaging devices surprise us with a more superior technology?

"Hageman in 2001,3 showed that proteins associated with inflammation and immune-mediated processes are prevalent among drusen-associated constituents and one of the best available markers of AMD risk is single nucleotide polymorphisms in complement factor H (CFH). As such, I hope that next year we will see some research showing that inhibition of complement factors block drusen formation in certain patients," said Dr Mauget-Faysse.

            

    

    

Professor Rizzo, on the other hand, believes that we will see more and more studies advocating combination approaches to AMD therapy and the treatment of other retinopathies. He also thinks that we will see further improvements to MIVS instrumentation and techniques that allow surgeons to further reduce surgical trauma and increase patient comfort. "I also think that implants, which deliver sustained-release drug therapy for the treatment of DME will continue to yield impressive results in 2008," he hypothesized.

Dr Stefansson agrees that the benefits of combination therapies and surgery/therapeutic combinations will dominate the headlines in 2008. Meanwhile, he also hopes that studies touting the benefits of retinal oximetry will also be announced next year.

"I sincerely believe that we will see a shift from 'monotherapeutic thinking' to 'oncologic thinking' in terms of our treatment approaches. I also expect more interest in diabetic retinopathy. Dry AMD and prevention will also be a hot topic," concluded Professor Augustin.

References
1. A.J. Augustin, et al. Retina February 2007;27(2):133-140.
2. M. Inoue, et al. Am. J. Ophthalmol. November 2004;138(5):867-869.
3. G.S. Hageman et al. Prog. Retina Eye Res. 2001;20:705-732

Special contributors

                            

Prof. Dr. Albert L. Augustin             Professor Stanislao Rizzo

                            

Martine Mauget-Faysse, MD             Einar Stefansson, MD, PhD

1, 2, 3, 4, 5

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.